NEUROMEDICAL SYSTEMS' LAUNCHING PAPNET ANALYZER DEC. 1 AT PRICE TO LABS OF $18 PER TEST; PLANNED IPO TO NET $75.1 MIL., FUND MARKETING AND EXPANSION EFFORT
This article was originally published in The Gray Sheet
Neuromedical Systems, Inc. is rolling out its Papnet adjunctive Pap smear analyzer Dec. 1 following FDA approval of the product's premarket approval application Nov. 8. Neuromedical Systems, Inc. is offering the system, designed to increase detection of positive samples, to labs at a cost of $18 per slide. NSI estimates the cost to patients at $35.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.